Chimeric Therapeutics Company Top Insiders
| CHMMF Stock | 0 0.00 0.00% |
Chimeric Therapeutics employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Examination of Chimeric Therapeutics' management performance can provide insight into the company performance.
| Eliot Bourk Insider Chief Innovation |
| Kelly Thornburg Insider VP Quality |
Chimeric |
Chimeric Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2552) % which means that it has lost $0.2552 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Chimeric Therapeutics' management efficiency ratios could be used to measure how well Chimeric Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Chimeric Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Chimeric Therapeutics Price Series Summation is a cross summation of Chimeric Therapeutics price series and its benchmark/peer.
Chimeric Therapeutics Notable Stakeholders
A Chimeric Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chimeric Therapeutics often face trade-offs trying to please all of them. Chimeric Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chimeric Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eliot Bourk | Chief Innovation | Profile | |
| Kelly Thornburg | VP Quality | Profile | |
| Jason MD | Chief Officer | Profile | |
| Nathan CA | Company Sec | Profile | |
| Jennifer Chow | MD CEO | Profile | |
| Bus CA | Sec | Profile | |
| Li Ren | VP Operations | Profile |
About Chimeric Therapeutics Management Performance
The success or failure of an entity such as Chimeric Therapeutics often depends on how effective the management is. Chimeric Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chimeric management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chimeric management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Chimeric Therapeutics Workforce Analysis
Traditionally, organizations such as Chimeric Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chimeric Therapeutics within its industry.Chimeric Therapeutics Manpower Efficiency
Return on Chimeric Therapeutics Manpower
| Revenue Per Employee | 373.9K | |
| Revenue Per Executive | 373.9K | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 2.3M |
Complementary Tools for Chimeric Pink Sheet analysis
When running Chimeric Therapeutics' price analysis, check to measure Chimeric Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimeric Therapeutics is operating at the current time. Most of Chimeric Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chimeric Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimeric Therapeutics' price. Additionally, you may evaluate how the addition of Chimeric Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |